Nobe O, Kubo H, Yoshii K, Tashiro M
Jpn J Antibiot. 1979 Mar;32(3):463-9.
NK 631, a new derivative of bleomycin, was clinically used in 14 cases of malignant tumors of skin. The results obtained were remarkably effective in 7 cases, effective in 3 cases, slightly effective in 2 cases and ineffective in 2 cases. The effective ratio was 71% when calculated regarding slightly effective as ineffective. Compared with bleomycin, we were impressed that the side effects observed with NK 631 were similar to those with bleomycin, but the influences for lung were smaller and slighter than the latter.
博来霉素新衍生物 NK631 临床应用于 14 例皮肤恶性肿瘤患者。结果显示,7 例显效,3 例有效,2 例微效,2 例无效。若将微效计为无效,则有效率为 71%。与博来霉素相比,NK631 的副作用与博来霉素相似,但对肺部的影响比后者更小、更轻微。